A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
GlobalData on MSN6d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science ...
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Nations Financial Group Inc. IA ADV lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 10.3% in ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s shares closed yesterday at $54.98. See what stocks ...
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback